Data Supporting BeyondSpring's Lead Asset, Plinabulin, to be Presented at WCLC 2015

NEW YORK, Sept. 1, 2015 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced the presentation of an investigator initiated study supporting its lead compound, Plinabulin, at the upcoming 16th World Conference on Lung Cancer (WCLC), which is hosted by the International Association for the Study of Lung Cancer (IASLC), and takes place September 6-9, 2015 in Denver, CO.

The research team led by Dr. Lyudmila Bazhenova of Moores Cancer Center, University of California San Diego (UCSD), has established a Phase I study to evaluate the combination of Plinabulin and Nivolumab in patients with metastatic squamous non-small cell lung cancer (NSCLC). The full details of the presentation are provided below.

  • Abstract #602 / P2.01-087: A Phase 1 Trial Combining Plinabulin and Nivolumab for Metastatic Squamous NSCLC
First / Presenting Author: Dr. Shihfan Yeh
Poster Session: Treatment of Advanced Diseases – NSCLC
Date, Time: Tue, September 8; 9:30 a.m. – 5:00 p.m. MT
Location: Exhibit Hall (Hall B+C)

Dr. Lyudmila Bazhenova, Medical Oncologist and Principal Investigator, UCSD, commented, "We are pleased to present our study evaluating the immune modulatory effect of Plinabulin in lung cancer at the upcoming WCLC 2015, a major gathering of clinicians and researchers in the field of lung and thoracic malignancies. This phase 1b/2 study, which we plan to initiate in the fourth quarter of 2015, is aimed at investigating the potential synergistic efficacy between Plinabulin and Nivolumab in patients suffering from metastatic squamous NSCLC and we look forward to sharing the study design."

About BeyondSpring Pharmaceuticals

BeyondSpring Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring is focused on the advancement and commercialization of Plinabulin, a novel, Phase 3-ready cancer therapeutic initially targeting non-small-cell lung cancer (NSCLC). Led by an expert management team consisting of pharmaceutical industry veterans from the U.S. and China, the Company is well positioned to further advance lead product candidate, Plinabulin. For more information, visit

CONTACT: The Ruth Group Lee Roth (investors) (646) 536-7012 Kirsten Thomas (media) (646) 536-7014

Source:BeyondSpring Pharmaceuticals